Consolidated statements of stockholders' equity (deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Stockholders' equity, balance at beginning of the period (Predecessor) at Dec. 31, 2016	$ (1,042,153)	$ 14	$ 425,231	$ (1,467,398)
Balance at beginning of period (in shares) (Predecessor) at Dec. 31, 2016		1,392,706
Restricted stock forfeited | Predecessor		(1,454)
Restricted stock cancelled | Predecessor		(8,964)
Stock-based compensation | Predecessor	194		194
Net income (loss) | Predecessor	1,041,959			1,041,959
Stockholders' equity, balance at end of the period (Predecessor) at Mar. 21, 2017	(1,012,089)	$ 14	425,425	(425,439)
Stockholders' equity, balance at end of the period at Mar. 21, 2017	$ 949,063	$ 450	948,613
Balance at end of period (in shares) (Predecessor) at Mar. 21, 2017		1,382,288
Balance at end of period (in shares) at Mar. 21, 2017	44,982,142	44,982,142
Cancellation of equity | Predecessor		$ (14)	(425,425)	425,439
Cancellation of equity (in shares) | Predecessor		(1,382,288)
Issuance of Successor common stock - rights offering	$ 50,027	$ 42	49,985
Issuance of Successor common stock - rights offering (in shares)		4,197,210
Issuance of Successor common stock - backstop premium	4	$ 4
Issuance of Successor common stock - backstop premium (in shares)		367,030
Issuance of Successor common stock - settlement of claims	898,914	$ 404	898,510
Issuance of Successor common stock - settlement of claims (in shares)		40,417,902
Issuance of Successor warrants	118		118
Stock-based compensation	3,577	$ 18	3,559
Stock-based compensation (in shares)		1,796,943
Net income (loss)	(17,433)			(17,433)
Stockholders' equity, balance at end of the period at Sep. 30, 2017	$ 935,207	$ 468	$ 952,172	$ (17,433)
Balance at end of period (in shares) at Sep. 30, 2017		46,779,085